Please use this identifier to cite or link to this item:
https://doi.org/10.3390/ijms20020269
DC Field | Value | |
---|---|---|
dc.title | Sevoflurane, propofol and carvedilol block myocardial protection by limb remote ischemic preconditioning | |
dc.contributor.author | Cho, Y.J | |
dc.contributor.author | Nam, K | |
dc.contributor.author | Kim, T.K | |
dc.contributor.author | Choi, S.W | |
dc.contributor.author | Kim, S.J | |
dc.contributor.author | Hausenloy, D.J | |
dc.contributor.author | Jeon, Y | |
dc.date.accessioned | 2020-11-10T00:48:08Z | |
dc.date.available | 2020-11-10T00:48:08Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Cho, Y.J, Nam, K, Kim, T.K, Choi, S.W, Kim, S.J, Hausenloy, D.J, Jeon, Y (2019). Sevoflurane, propofol and carvedilol block myocardial protection by limb remote ischemic preconditioning. International Journal of Molecular Sciences 20 (2) : 269. ScholarBank@NUS Repository. https://doi.org/10.3390/ijms20020269 | |
dc.identifier.issn | 16616596 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/183295 | |
dc.description.abstract | The effects of remote ischemic preconditioning (RIPC) in cardiac surgery have been inconsistent. We investigated whether anesthesia or beta-blockers interfere with RIPC cardioprotection. Fifty patients undergoing cardiac surgery were randomized to receive limb RIPC (four cycles of 5-min of upper arm cuff inflation/deflation) in the awake state (no-anesthesia; n = 17), or under sevoflurane (n = 17) or propofol (n = 16) anesthesia. In a separate crossover study, 11 healthy volunteers received either carvedilol or no medication prior to RIPC. Plasma dialysates were obtained and perfused through an isolated male Sprague–Dawley rat heart subjected to 30-min ischemia/60-min reperfusion, following which myocardial infarct (MI) size was determined. In the cardiac surgery study, pre-RIPC MI sizes were similar among the groups (39.7 ± 4.5% no-anesthesia, 38.9 ± 5.3% sevoflurane, and 38.6 ± 3.6% propofol). However, post-RIPC MI size was reduced in the no-anesthesia group (27.5 ± 8.0%; p < 0.001), but not in the anesthesia groups (35.7 ± 6.9% sevoflurane and 35.8 ± 5.8% propofol). In the healthy volunteer study, there was a reduction in MI size with RIPC in the no-carvedilol group (41.7 ± 4.3% to 30.6 ± 8.5%; p < 0.0001), but not in the carvedilol group (41.0 ± 4.0% to 39.6 ± 5.6%; p = 0.452). We found that the cardioprotective effects of limb RIPC were abolished under propofol or sevoflurane anesthesia and in the presence of carvedilol therapy. © 2019 by the authors. Licensee MDPI, Basel, Switzerland. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20201031 | |
dc.subject | acetylsalicylic acid | |
dc.subject | angiotensin receptor antagonist | |
dc.subject | antidiabetic agent | |
dc.subject | beta adrenergic receptor blocking agent | |
dc.subject | caffeine | |
dc.subject | calcium channel blocking agent | |
dc.subject | carvedilol | |
dc.subject | clopidogrel | |
dc.subject | digoxin | |
dc.subject | dipeptidyl carboxypeptidase inhibitor | |
dc.subject | diuretic agent | |
dc.subject | glyceryl trinitrate | |
dc.subject | heparin | |
dc.subject | hydroxymethylglutaryl coenzyme A reductase inhibitor | |
dc.subject | insulin | |
dc.subject | midazolam | |
dc.subject | propofol | |
dc.subject | remifentanil | |
dc.subject | sevoflurane | |
dc.subject | sojourn | |
dc.subject | troponin | |
dc.subject | carvedilol | |
dc.subject | propofol | |
dc.subject | sevoflurane | |
dc.subject | acute heart infarction | |
dc.subject | adrenergic system | |
dc.subject | adult | |
dc.subject | animal experiment | |
dc.subject | animal model | |
dc.subject | arteriovenous fistula | |
dc.subject | artery injury | |
dc.subject | Article | |
dc.subject | bispectral index | |
dc.subject | blood pressure monitoring | |
dc.subject | body mass | |
dc.subject | body surface | |
dc.subject | cannulation | |
dc.subject | continuous infusion | |
dc.subject | controlled study | |
dc.subject | coronary artery bypass graft | |
dc.subject | dialysate level | |
dc.subject | electrocardiogram | |
dc.subject | estimated glomerular filtration rate | |
dc.subject | exercise | |
dc.subject | female | |
dc.subject | heart function | |
dc.subject | heart infarction prevention | |
dc.subject | heart left ventricle ejection fraction | |
dc.subject | heart muscle contractility | |
dc.subject | heart perfusion | |
dc.subject | heart protection | |
dc.subject | heart surgery | |
dc.subject | heart ventricle fibrillation | |
dc.subject | hematocrit | |
dc.subject | hemodialysis | |
dc.subject | human | |
dc.subject | human experiment | |
dc.subject | ischemic preconditioning | |
dc.subject | isolated heart | |
dc.subject | limit of detection | |
dc.subject | limit of quantitation | |
dc.subject | male | |
dc.subject | middle aged | |
dc.subject | nonhuman | |
dc.subject | normal human | |
dc.subject | parasympathetic nerve cell | |
dc.subject | percutaneous coronary intervention | |
dc.subject | pulse oximetry | |
dc.subject | rat | |
dc.subject | retrospective study | |
dc.subject | single drug dose | |
dc.subject | young adult | |
dc.subject | aged | |
dc.subject | animal | |
dc.subject | case control study | |
dc.subject | crossover procedure | |
dc.subject | disease model | |
dc.subject | heart infarction | |
dc.subject | limb | |
dc.subject | procedures | |
dc.subject | randomization | |
dc.subject | Sprague Dawley rat | |
dc.subject | vascularization | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Animals | |
dc.subject | Cardiac Surgical Procedures | |
dc.subject | Carvedilol | |
dc.subject | Case-Control Studies | |
dc.subject | Cross-Over Studies | |
dc.subject | Disease Models, Animal | |
dc.subject | Extremities | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Ischemic Preconditioning | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Myocardial Infarction | |
dc.subject | Propofol | |
dc.subject | Random Allocation | |
dc.subject | Rats | |
dc.subject | Rats, Sprague-Dawley | |
dc.subject | Sevoflurane | |
dc.type | Article | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.3390/ijms20020269 | |
dc.description.sourcetitle | International Journal of Molecular Sciences | |
dc.description.volume | 20 | |
dc.description.issue | 2 | |
dc.description.page | 269 | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_3390_ijms20020269.pdf | 2.94 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License